Irritable bowel syndrome and food allergy in children

Cover Page

Abstract


Dysplasia of the main veins (DMV) is known by the names of authors had described this pathology as the Klippel-Trenone syndrome (KTS). Many authors consider the cause of the syndrome to be the impact of various teratogenic factors. These include drugs, infectious agents, radiation exposure, domestic and occupational hazards. Teratogenic factors can damage embryo vessels, causing local stasis and hemorrhages, which can be cause for the perverse formation of veins and surrounding tissues. The clinical picture of severe and extremely severe degrees embryonic type DMV is quite simple. It include asymmetric hypertrophy of the extremities, “disfiguring” in patients with extremely severe degree, extensive cyanotic vascular spots, often accompanied by papillomatous nevus of the skin. The spots are located on the anterolateral surface of the thigh and lower leg. Embryonic veins, which can be found under the spots – a characteristic pathognomonic sign of the KTS. Disturbances in the shape of the limb and external signs of angiodysplasia (vascular spots, atypical veins) in children with mild to moderate severity degree are less pronounced and can be inconstant. Examination and treatment of children with DMV, depending on the severity of the lesion, it is rational to start from the time of detection to 6 years. Phlebography reveal various variants of violation of the surgical anatomy of the veins of the affected limbs. Medium and light forms of dysplasia of the main veins should be differentiated with similar forms of fetal type, congenital Parkes Weber syndrome and acquired iliofemoral thrombosis (atypical veins above the bosom). Sometimes there are combinations of dysplasia of the main, deep, intermuscular and superficial veins. The following operations, according to the indications, are performed: phlebectomy and perforant veins ligation; embryonic veins removal and main outflow correction; musculoskeletal system surgery, abdominal and retroperitoneal surgery, as well as amputation of affected limb. Treatment including surgical and non-surgical methods should be comprehensive and should be performed in highly specialized, multidisciplinary hospitals.


The relationship between systemic allergic disorders and irritable bowel syndrome (IBS) is an area of intense interest [3]. Several studies demonstrated that the incidence of IBS was higher in patients with bronchial asthma and those with bronchial obstructive syndrome among those without asthma [53], and a significant number of studies describe an increase in the frequency of IBS in patients with bronchial asthma and other atopic diseases [6, 18, 24, 41–43, 51]. Tobin et al. (2008) [51] described a distinct subgroup of patients with atopic IBS, who presented with typical IBS symptoms in combination with atopic symptoms. In a cohort study of 4,089 children, Olén et al. (2014) studied the relationship between atopic diseases and/or food sensitization and abdominal pain in 12-year-old adolescents [40] and found that 9% of the subjects experienced abdominal pain. The authors demonstrated that in children with bronchial asthma, allergic rhinitis, eczema and food sensitization, the risk of abdominal pain was higher, which increased in parallel with the increase in the number of allergic diseases in these subjects. Asthma in the first two years of life and food sensitization at the age of eight years were the most significant risk factors for abdominal pain at the age of 12 years [40]. A questionnaire survey of the parents of 2463 children conducted in St. Petersburg [5] also reported a similar frequency of abdominal pain in school-aged children (9.87%); interestingly, 28.8% (720) of the respondents reported various manifestations of food intolerance.

Studies also demonstrated the high incidence of IBS (93%) and the high prevalence of atopic diseases (approximately 60%) in adult patients with food allergies [36]. In 2010, Lillestol et al. assessed symptoms and response to the skin prick test and measured serum allergy marker levels (general and specific immunoglobulin [Ig]E, tryptase and eosinophilic cationic protein), intestinal permeability, IgE- and tryptase-positive cells and eosinophils in duodenal biopsy samples in patients with food allergies. They found that in patients with atopic diseases, compared to nonatopic patients, the intestinal permeability and the number of IgE-producing cells were increased; however, gastrointestinal symptoms did not differ between the two groups. Another study reported an increase in serum IgE levels of patients with IBS compared with the control subjects [36]. Overall, these observations suggest that some patients with food intolerance and atopy might have an IgE-mediated and mast cell-associated IBS component.

The role of mast cells in the IBS pathophysiology has been recently recognized [18, 51]. Surface receptors on mast cells enable binding of antigens with IgE, which promotes degranulation of the mast cells and the consistent release of inflammatory mediators including histamine, serotonin, and pro-inflammatory cytokines. The release of these mediators underlies the hyperresponsiveness that causes the clinical manifestations of atopy; these mediators also affect the nerve receptors and smooth muscle functions and lead to an increase in the permeability of the intestinal wall, which is closely related to the IBS pathogenesis [1, 2, 4, 17, 33, 51]. Numerous studies demonstrated an increase in the number of mast cells throughout the gastrointestinal tract in all IBS subtypes [22, 32, 33, 37], and visceral hypersensitivity was shown to positively correlate with the number of mast cells [13]. In addition, activation status of the mast cells and their interaction with nerve receptors was shown to be altered in IBS [14]. Administration of the mast cell stabilizer ketotifen was shown to reduce the visceral sensation of pain in patients with IBS compared with the placebo treatment [30]. All together, these findings provide abundant evidence for the role of mast cells in the IBS pathogenesis and emphasize the potential for investigation of new therapies.

One study revealed that basophils, in addition to mast cells, contributed to the pathogenesis of atopic diseases and IBS [47].

IgE plays a central role in the pathophysiology of type I hypersensitivity. After initial contact with an allergen, dendritic cells represent the allergen to antigen-specific T cells. In some individuals, T cells respond to this interaction by releasing a variety of cytokines, thus stimulating the development of B cells that can produce antigen-specific IgE. Circulating IgE binds to receptors on the surface of both mast cells andbasophils, and subsequent exposure to the allergen results in cross-linking of IgE molecules on mast cells and their degranulation [25]. To date, there is no conclusive evidence of the role of IgE-mediated allergic response in IBS, especially in patients with concomitant atopy. The studies on this topic are few, unrelated and contradictory; the methods used by these studies are also widely variable [8, 38, 44]. For example, in one study, 24 IBS patients, including 12 patients with atopy and 12 patients without atopy, underwent a blind food challenge after a three-week hypoallergenic diet. In 14 patients, one or more food products or food additives caused typical IBS symptoms, nine of whom (all from the atopy group) had elevated total serum IgE levels [44]. In a study on intestinal permeability that included 17 children with IBS state, starvation period followed by a specific food challenge led to postprandial changes in nine children; all nine children had a burdened history of allergies and/or a high total serum IgE and responded to the exclusion of food [44]. Elevated IgE fragment crystallizable (Fc) levels in fecal extracts were detected in 73% of patients with food allergy that was confirmed by prick tests and radioallergosorbent tests (RASTs). In contrast, none of the healthy subjects had detectable fecal IgE Fc. In subgroup analysis of the IBS patients, IgE Fc was found in the feces of 22 of the 32 patients (68.8%). Simultaneous measurement of alpha-I antitrypsin in blood serum and feces eliminated the possibility of extravasation of plasma proteins (including IgE) as the cause of these results [8]. In another study, the incidence of total IgE increase in IBS was found to be 34.5% [38].

The role of allergy in the IBS pathogenesis was also studied using anamnesis; prick test; determination of total IgE level and specific IgEs against food allergens, and eosinophilia; and intestinal challenge with food allergens by colonoscopy. In a study, the frequency of food allergy based on immunological tests was 14.4%, and the diagnosis was confirmed in 3.2% of the cases utilizing endoscopic challenge [16]. Interestingly, in another study including 20 IBS patients who developed gastrointestinal symptoms after wheat intake, the elimination diet led to the resolution of symptoms, which returned after the challenge. Although only 50% of the patients were seropositive for wheat-specific IgE, immunoblot analysis revealed that IgE was bound to both the soluble and insoluble wheat proteins all patients [48]. The authors concluded that the traditional methods used to diagnose IgE-mediated hypersensitivity were inadequate for allergological screening of the subgroup of patients with IBS. To explain their results, the authors proposed two hypotheses: 1) low serum IgE levels; 2) the inadequacy of the currently used methods for the diagnosis of food allergies to wheat. These possibilities explain why enteropathy caused by wheat-specific IgE is rarely diagnosed.

Many studies reported the discrepancy between the anamnestic data on reactions to food products and the results of immunological tests [28, 49, 52]. For example, a study found that there was no correlation between the patients’ allergies and test results: While the patients reported intolerance to dairy products, raw foods, spicy foods, coffee, and alcohol, the tests indicated intolerance to fish, rice, wheat, sweet potato, celery, and onions [28]. The IgE-mediated allergic reactions were proposed to be localized in the intestinal mucosa. In one study using сolonoscopic allergen provocation (COLAP) in 70 patients with IBS and clinical findings of food allergy as well as 5 healthy volunteers, the patients were evaluated 20 minutes after the injection of three allergens (milk, wheat, and hazelnut) into the mucosal membrane of the blind intestine. These allergens were selected individually, taking into account each patient’s anamnesis and the presence of specific IgEs in the serum. The evaluation was performed by a semi-quantitative method that evaluated the presence of hyperemia and bullas using a scale ranging from 0 to 4. A reaction with a score of 2 or more was considered positive. In 74% of the IBS patients, the COLAP test was positive in response to at least one food allergen, whereas none of the healthy volunteers had a reaction [16]. Biopsy specimens from the sites with a positive response showed an increase in the number of mast cells and eosinophilic infiltration. A subsequent three-month elimination diet in the COLAP-positive patients was effective in 89% of the cases. The strong correlation of the clinical data with COLAP, which was poorly correlated with the skin prick test and the level of specific serum IgE, suggest that COLAP might aid in the identification of local IgE-mediated mechanisms [16, 31]. In another study, COLAP using cow milk protein as an allergen confirmed the association of IBS with allergy to cow milk protein, which was not associated with serum specific IgE or IgG/IgA [34].

The response to the cavitary administration of antigens was previously demonstrated by visualization with endosonography, transabdominal ultrasonography, magnetic resonance imaging, and confocal laser endomicroscopy [7, 10, 11, 21]. The thickening of the intestinal walls, increased peristalsis, and influx of large amounts of fluid into the lumen were noted, which are typical for IgE-mediated food allergy reactions due to the degranulation and release of mediators from the mucosal mast cells [36, 46].

Successful treatment of IBS patients with administration of monoclonal antibodies against IgE provides further support for the IgE’s role in the pathogenesis of IBS, at least in some patients [36, 46].

A number of studies investigating non-IgE-allergic reactions in IBS revealed that the IgG4 subclass, which is produced in response to T2 cytokines, can lead to the release of histamine as well as IgE antibodies [15, 29]. Serum IgG and IgG4 levels are higher in patients with IBS and food allergy, which might be due to the selective permeability of the intestine to food allergens. Previous studies investigated the pathogenesis of the increase in the level of specific IgG and IgG4 antibodies in IBS and allergies and whether this was a specific or nonspecific response to an increase in the permeability of the intestinal mucosa [9, 12, 19, 23, 39, 45, 54]. Although some studies found that the elevation in IgG levels and production of IgG4 might be part of a normal immune response to food antigens [20, 27, 50], most studies suggest that assessment of both specific IgG4 and IgE antibodies to food allergens might be useful for evaluating food allergy in IBS patients [45]. Thus, elimination diets based on specific IgG4 antibodies were demonstrated to achieve a significant clinical effect in several studies [9, 12, 19, 23, 39, 54]. A systematic review of seven clinical trials revealed that the efficacy of this type of diet selection ranged from 15% to 71% and that the most frequently excluded foods were milk, wheat, eggs, potatoes, and celery [39]. Nevertheless, the methodologies in these studies were not always adequate, which limited the validity of the results, especially since some of the studies failed to find a correlation between the level of IgG4 antibodies and the presence of symptoms [35, 55].

Thus, to date, albeit the obvious relationship between food allergy and IBS, the underlying mechanisms should be further elucidated in future studies. Whether IBS or food allergy is the cause and whether intestinal symptoms in patients with allergic diseases is a manifestation of a systemic allergic condition or IBS remain unclear. Answers to these questions will open up new prospects for using an elimination diet to treat IBS patients.

Valeria P. Novikova

St. Petersburg State Pediatric Medical University

Author for correspondence.
Email: novikova-vp@mail.ru

Russian Federation, Saint Petersburg

MD, PhD, Dr Med Sci, Professor, Head, Laboratory of Medical and Social Problems in Pediatrics, Research Center

Maria O. Revnova

St. Petersburg State Pediatric Medical University

Email: revnoff@mail.ru

Russian Federation, Saint Petersburg

MD, PhD, Dr Med Sci, Professor, Head, Department of Outpatient Pediatrics n.a. A.F. Tour

Anastasia P. Listopadova

St. Petersburg State Pediatric Medical University

Email: a.listopadova@mail.ru

Russian Federation, Saint Petersburg

MD, PhD, Senior Researcher, Laboratory of Medical and Social Problems in Pediatrics, Research Center

  1. Барановский А.Ю., Кондрашина Э.А. Дисбактериоз и дисбиоз кишечника. - СПб., 2000. [Baranovskij AYu, Kondrashina EA. Disbakterioz i disbioz kishechnika. Saint Petersburg; 2000. (In Russ.)]
  2. Барановский А.Ю., Кондрашина Э.А. Дисбактериоз и дисбиоз кишечника. Сер. «Краткое руководство» (2-е изд., исправл.). - СПб., 2002. [Baranovskij AYu, Kondrashina EA. Disbakterioz i disbioz kishechnika. Ser. “Kratkoe rukovodstvo” (2nd edition). Saint Petersburg; 2002. (In Russ.)]
  3. Бельмер С.В.,Хавкин А.И., Печкуров Д.В. Функциональные расстройства органов пищеварения у детей (в свете Римских критериев IV). - М.: Ремдер, 2016. [Bel'mer SV, Khavkin AI, Pechkurov DV. Functional disorders of the digestive system in children (in light of the Rome criteria IV). Moscow: Remder; 2016. (In Russ.)]
  4. Васильев Б.Я., Васильева Р.И., Лобзин Ю.В. Острые кишечные заболевания: ротавирусы и ротавирусная инфекция. - СПб., 2000. [Vasilev BYa, Vasileva RI, Lobzin YuV. Ostrye kishechnye zabolevaniya: rotavirusy i rotavirusnaya infekciya. Saint Petersburg; 2000. (In Russ.)]
  5. Гурина О.П., Дементьева Е.А., Блинов А.Е., и др. Особенности иммунного реагирования при атопии у детей // Педиатр. - 2014. - Т. 5. - № 4. - С. 95-103. Gurina OP, Dement'yeva EA, Blinov AE, et al. Characteristics of the immune response in children with atopic disorders. Pediatrician (St. Petersburg). 2014;5(4):95-103. (In Russ.)]
  6. Намазова-Баранова Л.С., Алексеева А.А., Алтунин В.В., и др. Аллергия у детей: от теории - к практике. - М., 2011. [Namazova-Baranova LS, Alekseeva AA, Altunin VV, et al. Allergiya u detej: ot teorii - k praktike. Moscow; 2011. (In Russ.)]
  7. Саблин О.А., Гриневич В.Б., Успенский Ю.П., Ратников В.А. Функциональная диагностика в гастроэнтерологии: Учебно-методическое пособие. - СПб., 2002. [Sablin OA, Grinevich VB, Uspenskij YuP, Ratnikov VA. Funkcionalnaya diagnostika v gastroenterologii. Uchebno-metodicheskoe posobie. Saint Petersburg; 2002. (In Russ.)]
  8. André F, André C, Colin L, Cavagna S. IgE in stools as indicator of food sensitization. Allergy. 1995;50(4):328-33. doi: 10.1111/j.1398-9995.1995.tb01156.x.
  9. Aydinlar EI, Dikmen PY, Tiftikci A, et al. IgG-based elimination diet in migraine plus irritable bowel syndrome. Headache. 2013;53(3):514-525. doi: 10.1111/j.1526-4610.2012.02296.x.
  10. Arslan G, Gilja OH, Lind R, et al. Response to intestinal provocation monitored by transabdominal ultrasound in patients with food hypersensitivity. Scand J Gastroenterol. 2009;40(4):386-394. doi: 10.1080/00365520510012163.
  11. Arslan G, Lillestol K, Mulahasanovic A, et al. Food hypersensitivity reactions visualised by ultrasonography and magnetic resonance imaging in a patient lacking systemic food-specific IgE. Digestion. 2006;73(2-3): 111-115. doi: 10.1159/000094042.
  12. Atkinson W, Sheldon TA, Shaath N, Whorwell PJ. Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial. Gut. 2004;53(10): 1459-1464. doi: 10.1136/gut.2003.037697.
  13. Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004;126(3):693-702. doi: 10.1053/j.gastro.2003.11.055.
  14. Braak B, Klooker TK, Wouters MM, et al. Mucosal immune cell numbers and visceral sensitivity in patients with irritable bowel syndrome: is there any relationship? Am J Gastroenterol. 2012;107(5):715-26. doi: 10.1038/ajg.2012.54.
  15. Brito-Zeron P, Ramos-Casals M, Bosch X, Stone JH. The clinical spectrum of IgG4-related disease. Autoimmun Rev. 2014;13(12):1203-1210. doi: 10.1016/j.autrev.2014.08.013.
  16. Bischoff SC, Herrmann A, Manns MP. Prevalence of adverse reactions to food in patients with gastrointestinal disease. Allergy. 1996;51(11):811-818. doi: 10.1111/j.1398-9995.1996.tb04471.x.
  17. Bousquet J, Cabrera P, Berkman N, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy. 2005;60(3):302-308. doi: 10.1111/j.1398-9995.2004.00770.x.
  18. Cole JA, Rothman KJ, Cabral HJ, et al. Incidence of IBS in a cohort of people with asthma. Dig Dis Sci. 2007;52(2): 329-335. doi: 10.1007/s10620-006-9530-5.
  19. Drisko J, Bischoff B, Hall M, McCallum R. Treating Irritable Bowel Syndrome with a Food Elimination Diet Followed by Food Challenge and Probiotics. J Am Coll Nutr. 2006;25(6):514-522. doi: 10.1080/07315724.2006.10719567.
  20. Fälth-Magnusson K, Kjellman NIM, Magnusson KE. Antibodies IgG, IgA, and IgM to food antigens during the first 18 months of life in relation to feeding and development of atopic disease. J Allergy Clin Immunol. 1988;81(4):743-749. doi: 10.1016/0091-6749(88)91048-2.
  21. Fritscher-Ravens A, Schuppan D, Ellrichmann M, et al. Confocal endomicroscopy shows food-associated changes in the intestinal mucosa of patients with irritable bowel syndrome. Gastroenterology. 2014;147(5):1012-1020 e1014. doi: 10.1053/j.gastro.2014.07.046.
  22. Guilarte M, Santos J, de Torres I, et al. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut. 2007;56(2):203-9. doi: 10.1136/gut.2006.100594.
  23. Guo H, Jiang T, Wang J, et al. The value of eliminating foods according to food-specific immunoglobulin G antibodies in irritable bowel syndrome with diarrhoea. J Int Med Res. 2012;40(1):204-210. doi: 10.1177/147323001204000121.
  24. Hunskar GS, Langeland N, Wensaas KA, et al. The impact of atopic disease on the risk of post-infectious fatigue and irritable bowel syndrome 3 years after Giardia infection. A historic cohort study. Scand J Gastroenterol. 2012;47(8-9):956-961. doi: 10.3109/00365521.2012.696681.
  25. Pearson JS, Niven RM, Meng J, et al. Immunoglobulin E in irritable bowel syndrome: another target for treatment? A case report and literature review. Therap Adv Gastroenterol. 2015;8(5):270-277. doi: 10.1177/1756283X15588875.
  26. Jones MP, Walker MM, Ford AC, Talley NJ. The overlap of atopy and functional gastrointestinal disorders among 23,471 patients in primary care. Aliment Pharmacol Ther. 2014;40(4):382-391. doi: 10.1111/apt.12846.
  27. Johansson SG, Dannaeus A, Lilja G. The relevance of anti-food antibodies for the diagnosis of food allergy. Ann Allergy. 1984;53(6 Pt 2):665-672.
  28. Jun D-W. Food intolerance and skin prick test in treated and untreated irritable bowel syndrome. World J Gastroenterol. 2006;12(15):2382. doi: 10.3748/wjg.v12.i15.2382.
  29. Kamisawa T, Zen Y, Pillai S, Stone JH. IgG4-related disease. Lancet. 2015;385(9976):1460-1471. doi: 10.1016/s0140-6736(14)60720-0.
  30. Klooker TK, Braak B, Koopman KE, et al. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut. 2010;59(9):1213-1221. doi: 10.1136/gut.2010.213108.
  31. Kristjansson G, Serra J, Loof L, et al. Kinetics of mucosal granulocyte activation after gluten challenge in coeliac disease. Scand J Gastroenterol. 2005;40(6): 662-669. doi: 10.1080/00365520510015566.
  32. Laukoetter MG, Nava P, Nusrat A. Role of the intestinal barrier in inflammatory bowel disease. World J Gastroenterol. 2008;14(3):401. doi: 10.3748/wjg.14.401.
  33. Lee H, Park JH, Park DI, et al. Mucosal mast cell count is associated with intestinal permeability in patients with diarrhea predominant irritable bowel syndrome. J Neurogastroenterol Motil. 2013;19(2):244-250. doi: 10.5056/jnm.2013.19.2.244.
  34. Liden M, Kristjansson G, Valtysdottir S, et al. Cow's milk protein sensitivity assessed by the mucosal patch technique is related to irritable bowel syndrome in patients with primary Sjogren's syndrome. Clin Exp Allergy. 2008;38(6):929-935. doi: 10.1111/j.1365-2222.2008.02983.x.
  35. Ligaarden SC, Lydersen S, Farup PG. IgG and IgG4 antibodies in subjects with irritable bowel syndrome: a case control study in the general population. BMC Gastroenterol. 2012;12:166. doi: 10.1186/1471-230X-12-166.
  36. Lillestol K, Helgeland L, Arslan Lied G, et al. Indications of 'atopic bowel' in patients with self-reported food hypersensitivity. Aliment Pharmacol Ther. 2010;31(10):1112-1122. doi: 10.1111/j.1365-2036.2010.04261.x.
  37. Macsharry J, O'Mahony L, Fanning A, et al. Mucosal cytokine imbalance in irritable bowel syndrome. Scand J Gastroenterol. 2008;43(12):1467-1476. doi: 10.1080/00365520802276127.
  38. Mekkel G, Barta Z, Ress Z, et al. Increased IgE-type antibody response to food allergens in irritable bowel syndrome and inflammatory bowel diseases. Orv Hetil. 2005;146(17):797-802.
  39. Niec A. Are adverse food reactions linked to irritable bowel syndrome? Am J Gastroenterol. 1998;93(11):2184-2190. doi: 10.1111/j.1572-0241. 1998.00531.x.
  40. Olen O, Neuman A, Koopmann B, et al. Allergy-related diseases and recurrent abdominal pain during childhood - a birth cohort study. Aliment Pharmacol Ther. 2014;40(11-12):1349-1358. doi: 10.1111/apt.12965.
  41. Ozol D, Uz E, Bozalan R, et al. Relationship between asthma and irritable bowel syndrome: role of food allergy. J Asthma. 2006;43(10):773-775. doi: 10.1080/02770900601031789.
  42. Panicker R, Arifhodzic N, Al Ahmad M, Ali SA. Association and symptom characteristics of irritable bowel syndrome among bronchial asthma patients in Kuwait. Ann Thorac Med. 2010;5(1):37-42. doi: 10.4103/1817-1737.58958.
  43. Powell N, Huntley B, Beech T, et al. Increased prevalence of gastrointestinal symptoms in patients with allergic disease. Postgrad Med J. 2007;83(977):182-186. doi: 10.1136/pgmj.2006.049585.
  44. Petitpierre M, Gumowski P, Girard JP. Irritable bowel syndrome and hypersensitivity to food. Ann Allergy. 1985;54(6):538-540.
  45. el Rafei A, Peters SM, Harris N, Bellanti JA. Diagnostic value of IgG4 measurements in patients with food allergy. Ann Allergy. 1989;62(2):94-99.
  46. Santos J, Bayarri C, Saperas E, et al. Characterisation of immune mediator release during the immediate response to segmental mucosal challenge in the jejunum of patients with food allergy. Gut. 1999;45(4):553-558. doi: 10.1136/gut.45.4.553.
  47. Savage JH, Courneya JP, Sterba PM, et al. Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy. J Allergy Clin Immunol. 2012;130(5):1123-1129 e1122. doi: 10.1016/j.jaci.2012.05.039.
  48. Simonato B, De Lazzari F, Pasini G, et al. IgE binding to soluble and insoluble wheat flour proteins in atopic and non-atopic patients suffering from gastrointestinal symptoms after wheat ingestion. Clin Exp Allergy. 2001;31(11):1771-1778. doi: 10.1046/j.1365-2222.2001.01200.x.
  49. Soares RLS, Figueiredo HN, Maneschy CP, et al. Correlation between symptoms of the irritable bowel syndrome and the response to the food extract skin prick test. Braz J Med Biol Res. 2004;37(5):659-662. doi: 10.1590/s0100-879x2004000500005.
  50. Shanahan F, Whorwell PJ. IgG-mediated food intolerance in irritable bowel syndrome: a real phenomenon or an epiphenomenom? Am J Gastroenterol. 2005;100(7): 1558-9. doi: 10.1111/j.1572-0241.2005.50009.x.
  51. Tobin MC, Moparty B, Farhadi A, et al. Atopic irritable bowel syndrome: a novel subgroup of irritable bowel syndrome with allergic manifestations. Ann Allergy Asthma Immunol. 2008;100(1):49-53. doi: 10.1016/s1081-1206(10)60404-8.
  52. Uz E, Turkay C, Aytac S, Bavbek N. Risk factors for irritable bowel syndrome in Turkish population: role of food allergy. J Clin Gastroenterol. 2007;41(4):380-3. doi: 10.1097/01.mcg.0000225589.70706.24.
  53. White AM, Stevens WH, Upton AR, et al. Airway responsiveness to inhaled methacholine in patients with irritable bowel syndrome. Gastroenterology. 1991;100(1):68-74. doi: 10.1016/0016-5085(91)90584-8.
  54. Zar S, Mincher L, Benson MJ, Kumar D. Food-specific IgG4 antibody-guided exclusion diet improves symptoms and rectal compliance in irritable bowel syndrome. Scand J Gastroenterol. 2005;40(7):800-807. doi: 10.1080/00365520510015593.
  55. Zuo XL, Li YQ, Li WJ, et al. Alterations of food antigen-specific serum immunoglobulins G and E antibodies in patients with irritable bowel syndrome and functional dyspepsia. Clin Exp Allergy. 2007;37(6): 823-830. doi: 10.1111/j.1365-2222.2007.02727.x.

Views

Abstract - 197

PDF (Russian) - 61

PDF (English) - 62

Cited-By


PlumX


Copyright (c) 2018 Novikova V.P., Revnova M.O., Listopadova A.P.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies